Drug Target Review

MARCH 3, 2025

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. “For diseases like Parkinson’s, it’s more than sufficient,” he explains.

Disease 52

Disease Treatment Therapies Cell Biology 52

DrugBank

OCTOBER 4, 2024

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Drug Patent Watch

JULY 27, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs FDA 52

Drug Patent Watch

JANUARY 19, 2023

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs FDA 52

Drug Patent Watch

SEPTEMBER 27, 2020

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs FDA 52

Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”

Drugs 96

Drugs Drug Development Pharmaceuticals Production 96

Drug Patent Watch

SEPTEMBER 29, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

JULY 27, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

JANUARY 19, 2022

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

SEPTEMBER 28, 2021

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Drug Patent Watch

JANUARY 19, 2021

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceuticals Drugs FDA 40

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease 81

Disease Clinical Trials Trials Pharmaceutical Companies 81

Drug Patent Watch

JULY 26, 2024

Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The protection […] Source

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs Disease 52

Drug Target Review

JANUARY 8, 2024

It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. Through years of scientific exploration and research, we now know there are several biological changes that make our bodies more susceptible to disease or injury, and we can target those with therapeutic interventions.

Science 145

Science Disease FDA Approval Clinical Trials 145

Drug Target Review

AUGUST 6, 2024

A number of areas represent significant opportunities for Antibody Drug Conjugates (ADCs) beyond oncology, leveraging their ability to deliver therapeutic agents specifically to diseased cells or tissues while minimising off-target effects. Oncology also offers high returns and the opportunity to address severe, life-threatening conditions.

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

Drug Target Review

MARCH 4, 2025

A personalised approach to obesity treatment Traditional obesity treatments have often followed a one-size-fits-all model, despite mounting evidence that obesity is not a singular disease but rather a collection of subtypes. This growing health challenge increases the risk of diabetes, heart disease, and other conditions.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Broad Institute

DECEMBER 18, 2023

Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. Studies of Alzheimer's disease are teaching us that it's possible to measure some clinically important CSF biomarkers in blood.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

DrugBank

DECEMBER 18, 2024

A new shift is occurring in the pharmaceutical industry, leading to a rapidly expanding field known as digital therapeutics (DTx). These interventions target a broad spectrum of medical conditions, encompassing chronic diseases and even substance abuse. Healthcare providers also stand to gain significantly from DTx adoption.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

DrugBank

JANUARY 22, 2025

Environmental Impacts of Traditional Pharmaceutical Production Traditional pharmaceutical manufacturing is complex, with each phase contributing to environmental degradation. The extraction and synthesis of active pharmaceutical ingredients (API) utilize vast amounts of water and energy.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Production Government 52

Drug Target Review

SEPTEMBER 19, 2023

The chips can be modelled with primary cells, IPS derived stem cells or patient derived cells and potentiates to unlock molecular mechanisms that drive the disease pathophysiology, holding a greater promise. The first successful chip adaptation to a lung model was first described in 2010 by Donald Ingber, a bioengineer at Wyss institute.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

The Pharma Data

SEPTEMBER 3, 2020

Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Johnson & Johnson Announces that Janssen’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies. Source link.

Vaccine 52

Vaccine Disease Immune Response Pharmaceutical Companies 52

DrugBank

APRIL 12, 2024

Recently, the shift from an early-adopters market to an expansive early majority market in AI is undeniable, marking a universal shift among leaders in pharmaceuticals toward harnessing these technologies.  Stay tuned for part two coming soon. 

Drugs 98

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 98

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.

Disease 52

Disease Clinical Trials Trials Pharmaceutical Companies 52

Advarra

AUGUST 16, 2022

A rare, or orphan, disease by definition affects a small percentage of the population — fewer than 200,000 people in the U.S. But the numbers add up, and taken together, rare diseases impact an estimated 30 million Americans. Since then, the FDA has significantly changed its approach to rare and orphan diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Drug Target Review

SEPTEMBER 19, 2024

Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD). The treatment often initially provides good symptom relief and those affected by the disease can live a largely normal life.

Disease 52

Disease Drugs Treatment Drug Development 52

Drug Target Review

DECEMBER 11, 2024

This shift in focus is especially critical in toxicology, where accurate target analysis plays a vital role in identifying toxic effects and ensuring patient safety, particularly as the field transitions from traditional drugs to the promising realm of biotherapeutics, especially for rare diseases.

International 52

International Laboratories Drugs Pharmacokinetics 52

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

JULY 18, 2023

If we look at the pharmaceutical industry’s discovery and development success rate over the last 20 to 30 years, it has not improved, staying stubbornly at around 10 percent. Where AI can help us is to interrogate that biological question and make sure that we are identifying and drugging disease modifying targets in the right way.”

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

KIF1A

JULY 1, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. But promising drugs that didn’t make the cut for treating one disorder may still be effective for other rare diseases. What’s a pre-print?

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

PPD

AUGUST 16, 2023

However, as the world settles into its post-pandemic state and returns to pre-pandemic paradigms in many areas, the pharmaceutical industry remains dedicated to moving beyond traditional, centralized clinical trial constructs. However, the accessibility of advanced technologies enables the expansion of DCT models to other disease states.

Clinical Trials 98

Clinical Trials Trials Clinical Research FDA 98

DrugBank

JUNE 27, 2024

Currently, about one-third of recent drug approvals and 25% of the pharmaceutical industry's annual revenue is coming from repurposed drugs.This trend is being championed industry-wide, by public organizations and nonprofits, with numerous small companies diving in and academic publications on the subject showing great popularity.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

SCIENMAG: Medicine & Health

OCTOBER 4, 2023

In an article revealed today in Nature, scientists from deCODE Genetics, a subsidiary of the pharmaceutical company Amgen, demonstrated how plasma proteomics can contribute to a better understanding of diseases. Measuring a great […]

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Disease 52

Quanticate

SEPTEMBER 27, 2024

Each scientific field whether it be oncology , dermatology , rare disease , or others, presents unique challenges and opportunities that are crucial to improving patient outcomes, as well as guiding the efforts of researchers, physicians, and pharmaceutical companies in advancing healthcare solutions globally.

Clinical Research 52

Clinical Research Research Pharmaceutical Companies Science 52

DrugBank

SEPTEMBER 19, 2024

Oral drug delivery remains the gold standard in pharmaceutical administration. By utilizing these controlled-release technologies, pharmaceutical companies can tailor drug delivery to optimize treatment outcomes and improve patient experience. Nanoparticles can be tailored for passive or active targeting mechanisms.

Pharmacokinetics 98

Pharmacokinetics Drugs Treatment Disease 98

Drug Target Review

JULY 6, 2023

TPD is a rapidly evolving therapeutic modality to degrade a disease-causing proteins, thereby eliminating their function specifically. Undruggable versus druggable targets As elucidated by Shitaka, it is estimated that about 80 percent of the proteins involved in disease are undruggable targets. Nature News.

Targeted Protein Degradation 98

Targeted Protein Degradation Small Molecule Clinical Trials Science 98

The Pharma Data

JANUARY 5, 2021

RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases. We intend to use PWS as the anchor indication and will further investigate additional orphan disease opportunities in due course.”. Disease Highlights.

Disease 52

Disease FDA Approval Clinical Trials Trials 52